June 1, 2007
Abbott seeks approval for new stent system
By Cory Hopkins
Abbot Laboratories completed an application with the FDA to seek U.S. market approval for its latest coronary stent system.
Abbot, based in Illinois, operates a research facility in Worcester.
The company's XIENCE V Everolimus Eluting Coronary Stent System was launched in Europe and the Asia/Pacific region in 2006. It uses everolimus, a drug shown to effectively prevent coronary "re-narrowing" following stent applications, the company said.
In clinical trials, the Abbot stent was proven more effective than a major competitor's product, the company said.
Abbot, based in Illinois, operates a research facility in Worcester.
The company's XIENCE V Everolimus Eluting Coronary Stent System was launched in Europe and the Asia/Pacific region in 2006. It uses everolimus, a drug shown to effectively prevent coronary "re-narrowing" following stent applications, the company said.
In clinical trials, the Abbot stent was proven more effective than a major competitor's product, the company said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments